TC
PTLA

TwinBeech Capital’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

TwinBeech Capital’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-15,312
Closed -$366K – 544
2019
Q4 		$366K Buy
+15,312
New +$422K 0.11% 262

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

TwinBeech Capital's PTLA Position: Q1 2020 in Review

TwinBeech Capital sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2020, closing a stake of 15,312 shares — an estimated $366K sold.

TwinBeech Capital first reported a position in PTLA in Q4 2019 and held it in 1 quarter. The position peaked at $366K in Q4 2019. 187 funds tracked by Wall St. Rank hold PTLA as of Q1 2020.

  • TwinBeech Capital reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • TwinBeech Capital sold 15,312 Portola Pharmaceuticals, Inc. shares in Q1 2020, an estimated $366K.
  • TwinBeech Capital first reported a position in Portola Pharmaceuticals, Inc. in Q4 2019 and held it in 1 quarter.
  • TwinBeech Capital's Portola Pharmaceuticals, Inc. position peaked at $366K in Q4 2019.
  • 187 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2020.

Based on TwinBeech Capital's 13F filing for Q1 2020, filed 15 May 2020.